ABSTRACT
INTRODUCTION
Cervical cancer is in the fourth rank of cancer in females following breast cancer, lung cancer, and colorectal cancer. 1 There are 520,000 new patients worldwide each year. In Thailand, cervical cancer is the second most common cancer following breast cancer. 2 Every year, there are 8,100 new patients and 4,500 patients die from the disease. 3 According to the data from Hatyai Hospital, the numbers of patients increase every year. From 2011 to 2015, there were 570 patients with cervical cancer and 1,237 patients were diagnosed with cervical precancerous lesion. Cervical cancer takes several years to develop from cervical precancerous lesion to invasive cancer. However, cervical cancer can be screened. 4 Therefore, early diagnosis and treatment from cervical precancerous lesion would help to reduce the numbers of cervical cancer patients, particularly high-risk patients. Human immunodeficiency virus-infected patients are at risk of infection and cancers because of low immunity. Cervical carcinoma is one of the diseases with high prevalence in HIV patients. Its prevalence is about 20%. 5 The CD4 level affects the severity of cervical cancer, especially in HIV-infected patients because the immune deficiency increases the possibility of human papillomavirus infection and persistent infection. There was inconsistence between the effects of CD4 level and abnormal cervical cytology. Cardillo Therefore, the primary objective of this study was to determine the effects of high and low CD4 level on abnormal cervical cytology in HIV-infected women who have not received HAART. The secondary objective was to find the prevalence of abnormal cervical cytology in HIV-infected women who have not received HAART. Statistical analyses were performed using STATA version 13.0 (Stata Corp, College Station, Texas). The clinical data of the patients were analyzed by descriptive statistics. Continuous data were presented with mean ± standard deviation, median (1st, 3rd quartile). Data with normal distribution were analyzed by unpaired two-tailed t-test. Data with non-normal distribution were analyzed by Mann-Whitney U test. Discrete data were analyzed by Chi-square test, Fisher's exact test and odds ratio (95% confidence interval). For all analyses, p-value < 0.05 was considered statistically significant.
MATERIALS AND METHODS

This
RESULTS
The authors gathered information of 270 HIV-infected women who have not received HAART and had been screened for cervical cancer with Pap smear. A total of 135 patients had low CD4 level (CD4 < 200 cells/µL) and 135 patients had high CD4 level (CD4 ≥ 200 cells/µL). Most patients were 35 years or older (21-62 years old), accounted for 58.5% in the group with low CD4 level and 68.9% in the group with high CD4 level.
The correlation between CD4 level and patient characteristics: 24 patients with low CD4 level had two or more lifetime sexual partners, accounting for 17.8%. On the contrary, only four patients with high CD4 level had two or more lifetime sexual partners, accounting for 3% (p = 0.001). Other factors, including oral contraceptive use, smoking behavior, parity and sexually transmitted disease, were not statistically significant. Detailed result of patient characteristics is shown in Table 1 .
The median CD4 level in the low CD4 group was 60 cells/µL (25th percentile: 27 cells/µL, 75th percentile: 119 cells/µL), while median CD4 level in the high CD4 group was 342 cells/µL (25th percentile: 263 cells/µL, 75th percentile: 498 cells/µL). The difference of CD4 level between two groups was statistically significant (p < 0.001).
Of 270 HIV-infected women who have not received HAART, 70 patients had abnormal cervical cytology. Therefore, the prevalence of abnormal cervical cytology in HIV-infected women who have not received HAART was 25.9%. For the low CD4 group, abnormal cervical cytology was found in 47 patients. Thus, the prevalence of abnormal cervical cytology in this group was 37.8%, although 23 patients with abnormal cervical cytology were found in the high CD4 group. Therefore, the prevalence of abnormal cervical cytology in the high CD4 group was 17.0%. The prevalence of abnormal cervical cytology in both groups was the difference with statistical significance (p = 0.001). Odds ratio was 2.60 (95% confidence interval: 1.47-4.61).
The degrees of abnormal cervical cytology according to the 2001 Bethesda System 11 are shown in Table 2 .
None of the participants had atypical glandular cells, not otherwise specified (AGC-NOS), atypical glandular cells, favor neoplastic (AGC-FN), endocervical adenocarcinoma in situ (AIS), or adenocarcinoma. Furthermore, from data analysis of the low CD4 group compared with the high CD4 group, there was no significant difference in prevalence of patients with various degrees of abnormal cervical cytology.
DISCUSSION
Cervical cancer is the major public health problem in Thailand, particularly among HIV-infected patients. Human immunodeficiency virus infection reduces the immune system's ability to get rid of infections, causing low immunity that results in susceptibility to infection and causes cervical cancer intensified.
There was inconsistency between effects of CD4 level on abnormal cervical cytology. This research divided HIV-infected women into two groups based on CD4 level: high CD4 group (CD4 ≥ 200 cells/µL) and low CD4 group (CD4 < 200 cells/µL). The research focused on the HIV-infected women who have not received HAART. The patients' characteristics showed that two or more lifetime sexual partners are associated with low CD4 level with statistical significance. It can be assumed that having more sexual partners provides more opportunity to be infected with HIV in terms of both viral load and viral strain, causing worse immunity than women with fewer sexual partners. This finding was consistent with the study of Getinet et al. 12 Other factors, such as age, smoking behavior, oral contraceptive use, parity, and sexually transmitted disease had no significant difference between high and low CD4 groups.
The prevalence of abnormal cervical cytology in HIV-infected women who have not received HAART was 25.9% in this study. This was similar to the previous studies that reported about 20 to 27%. 9,13,14 However, Chalermchockcharoenkit et al 8 reported the prevalence of abnormal cervical cytology at 13.3%. Further study was conducted in 2011 and found that the prevalence of abnormal cervical cytology in HIV-infected women was 15.4%. 10 Inconsistent of the results may be from the participants of the present study were HAART naïve, while most participants in Chalermchockcharoenkit study had received HAART. Therefore, there is higher possibility of low immune patient in the present study, causing more chance of developing abnormal cervical cytology. Considering by high and low CD4 level, the prevalence of abnormal cervical cytology in the low CD4 group was 37.8%, which was 2.6 times higher than those with high . Moreover, the low CD4 group had higher prevalence of abnormal cervical cytology than the high CD4 group. However, the difference had no statistical significance. This present study had sufficient sample size to conclude that CD4 level less than 200 cells/µL was the risk factor of abnormal cervical cytology, compared with CD4 200 cells/µL or over, with 2.6 fold risk. Moreover, this study included only HAART-naïve patient. Thus, it could be clearly concluded that CD4 level affected development of abnormal cervical cytology in HIV-infected women. From this finding, the physician should determine CD4 level in HIV patients at first diagnosis because severity of CD4 level is associated with severity of abnormal cervical cytology. Moreover, the follow-up interval of patients with low CD4 level should be shorter compared with patients with high CD4 level or normal population.
However, there was no significant difference in prevalence of various degrees of abnormal cervical cytology, according to the 2001 Bethesda System. However, because the sample size of each subgroup was small, additional study of each subgroup and association with CD4 level would be necessary. Furthermore, this research was a retrospective study, so some data might not be complete, which is the limitation of this study.
CONCLUSION
The low CD4 level (CD4 < 200 cells/µL) in HIV-infected women who have not received HAART increased the risk of abnormal cytology 2.6 folds, compared with high CD4 level (CD4 ≥ 200 cells/µL). The prevalence of abnormal cervical cytology in HIV-infected women who had not received HAART was 25.9%.
